Edition:
United States

Haemonetics Corp (HAE.N)

HAE.N on New York Stock Exchange

39.57USD
4:02pm EDT
Change (% chg)

$-0.02 (-0.05%)
Prev Close
$39.59
Open
$39.24
Day's High
$39.78
Day's Low
$38.81
Volume
49,458
Avg. Vol
102,515
52-wk High
$41.64
52-wk Low
$25.98

Latest Key Developments (Source: Significant Developments)

Haemonetics reports Q3 EPS $0.30
Monday, 6 Feb 2017 06:15am EST 

Haemonetics Corp - : Q3 earnings per share $0.30 . Q3 adjusted earnings per share $0.43 . Says updates full year fiscal 2017 guidance . Reported Q3 fiscal 2017 revenue of $227.8 million, down 2 pct . Q3 earnings per share view $0.41, revenue view $220.3 million -- Thomson Reuters I/B/E/S . Sees 2017 gaap EPS in the high end range of $0.70 - $0.80 . Sees 2017 revenue in the high end range of $850mln - $875mln . Sees 2017 adjusted EPS in the high end range of $1.40 - $1.50 .Fy2017 earnings per share view $1.51, revenue view $873.5 million -- Thomson Reuters I/B/E/S.  Full Article

Haemonetics Q2 earnings $0.38/shr
Monday, 7 Nov 2016 06:00am EST 

Haemonetics Corp : Q2 2017 revenue of $220.3 million, flat with the second quarter of fiscal 2016 as reported, and up 1 percent in constant currency . Qtrly earnings per share $0.38 . Q2 earnings per share view $0.35, revenue view $210.7 million -- Thomson Reuters I/B/E/S . Reaffirms full year fiscal 2017 guidance .On track to achieve $40 million annual savings target.  Full Article

Haemonetics Corp Q1 adjusted earnings per share $0.25
Monday, 1 Aug 2016 06:38am EDT 

Haemonetics Corp : Q1 fiscal 2017 revenue of $210.0 million; Q1 earnings per share $0.20; Q1 adjusted earnings per share $0.25 . Q1 earnings per share view $0.28, revenue view $205.4 million -- Thomson Reuters I/B/E/S . Company affirmed its fiscal 2017 guidance .Full-year 2017 earnings per share view $1.45, revenue view $865.6 million -- Thomson Reuters I/B/E/S.  Full Article

Haemonetics appoints Bill Burke CFO
Monday, 1 Aug 2016 06:00am EDT 

Haemonetics Corp : Haemonetics appoints Bill Burke CFO .Burke will join company from Medtronic Inc.  Full Article

Haemonetics plans repositioning organization, reduce number of employees
Tuesday, 10 May 2016 06:02am EDT 

Haemonetics Corp : On may 6, 2016, co committed to a plan for repositioning organization and cost structure; this involves reduction in number of employees . Estimate actions will result in total pre-tax expenses of about $26 million, nearly all of charges will result in future cash outlays .Estimate that co will record substantially all these charges during fiscal 2017 - sec filing.  Full Article

Haemonetics Corp announces Christopher Simon as CEO
Monday, 9 May 2016 06:03pm EDT 

Haemonetics Corp : Haemonetics corporation announces Christopher Simon as president and chief executive officer .Chris currently serves as a senior partner of Mckinsey & Company.  Full Article

Haemonetics Corp sees FY 2017 adjusted earnings per share $1.40-$1.50
Monday, 9 May 2016 06:01pm EDT 

Haemonetics Corp : Haemonetics provides fiscal 2017 guidance . Sees FY 2017 adjusted earnings per share $1.40-$1.50 . FY2017 earnings per share view $1.55, revenue view $911.3 million -- Thomson Reuters I/B/E/S .Sees FY 2017 revenue $850 million to $875 million.  Full Article

Haemonetics Corp announces CFO's Retirement
Thursday, 14 Apr 2016 04:01am EDT 

Haemonetics Corp:Christopher Lindop , Chief Financial Officer and Executive Vice President, Business Development has announced retirement.Company announced it will immediately begin a search for Lindop's successor.  Full Article

Haemonetics Corp reaffirms FY 2016 guidance
Wednesday, 4 Nov 2015 06:00am EST 

Haemonetics Corp:Affirms FY 2016 Revenue to be within the range of $910 - $920 million.Affirms FY 2016 adjusted earnings guidance to a range of $1.65 - $1.75 per share.  Full Article

Haemonetics Corp lowers FY 2016 guidance; gives Q2 2016 guidance
Monday, 5 Oct 2015 04:30pm EDT 

Haemonetics Corp:Expects to report revenue about $220 million and adjusted earnings approximating $0.40 per share for Q2 2016.Says FY 2016 Revenue is now expected to be within the range of $910 - $920 million, representing 0-1% growth, which is below previous guidance of 4-6% growth.Says on constant currency basis, FY 2016 revenue growth approximating 4% is now forecasted, which is below previous forecasts of 7-9% growth.Says FY 2016 adjusted earnings guidance is revised to a range of $1.65 - $1.75 per share, which is below the previous guidance range of $1.98 - $2.08 per share.Says in constant currency FY 2016 adjusted operating income is expected to grow at about 4 pct.FY 2016 revenue of $947 million and EPS of $2.02 - Thomson Reuters I/B/E/S.Q2 2016 revenue of $226 million and EPS of $0.39 - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Haemonetics reports Q3 EPS $0.30

* Reported Q3 fiscal 2017 revenue of $227.8 million, down 2 pct